SpringerLink
Log in

A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study

  • Original Paper
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

To investigate the factors influencing the outcome of radioactive iodine (RAI) treatment in intermediate- to high-risk patients with differentiated thyroid carcinoma (DTC).

Methods

We enrolled 553 DTC patients who underwent total thyroidectomy and categorized them into two groups according to their response to RAI therapy: excellent response (ER) and non-ER groups. Clinical and pathological characteristics of the patients were collected and retrospectively analyzed using univariate and multivariate binary logistic regression. Receiver operating characteristic (ROC) curves and diagnostic cutoff values were analyzed to assess the predictive value of important quantitative influences on 131I treatment outcomes. A new nomogram model was developed based on the above independent risk factors. R software was used to develop nomograms with all the independent prognostic factors included.

Results

The multivariate analysis showed that lymph node metastasis (LNM), stimulated thyroglobulin (sTg), thyroglobulin antibodies (TgAb), and sTg/thyroid-stimulating hormone (TSH) were significantly associated with non-ER of DTC patients. In the training set, the consistency index (C-index) of the new column line graph was 0.868 (95% CI 0.865-0.871).

Conclusion

We proposed a new nomogram to predict non-ER for DTC with excellent discrimination and calibration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

References

  1. D.W. Chen, B.H.H. Lang, D.S.A. Mcleod et al. Thyroid cancer. Lancet 401(10387), 1531–1544 (2023). https://doi.org/10.1016/s0140-6736(23)00020-x

    Article  PubMed  Google Scholar 

  2. J.D. Lin, C. Hsueh, T.C. Chao, Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastasis. Medicine 94(26), e1063 (2015). https://doi.org/10.1097/md.0000000000001063

    Article  PubMed  PubMed Central  Google Scholar 

  3. M. Schlumberger, S. Leboulleux, Current practice in patients with differentiated thyroid cancer. Nat. Rev. Endocrinol. 17(3), 176–188 (2021). https://doi.org/10.1038/s41574-020-00448-z

    Article  CAS  PubMed  Google Scholar 

  4. B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020

    Article  PubMed  PubMed Central  Google Scholar 

  5. C. Sparano, S. Moog, J. Hadoux et al. Strategies for radioiodine treatment: what’s new. Cancers 14(15), (2022). https://doi.org/10.3390/cancers14153800

  6. Y. Lin, T. Li, J. Liang et al. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer. Clin. Nucl. Med. 36(12), 1102–1105 (2011). https://doi.org/10.1097/RLU.0b013e3182291c65

    Article  PubMed  Google Scholar 

  7. Y.W. Chang, H.S. Kim, S.P. Jung et al. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio. Int J. Clin. Oncol. 21(5), 862–868 (2016). https://doi.org/10.1007/s10147-016-0956-2

    Article  CAS  PubMed  Google Scholar 

  8. I.O. Amui, J.V. Tagliarini, E.C. Castilho et al. The first postoperative-stimulated serum thyroglobulin is a prognostic factor for thyroid microcarcinomas. Braz. J. Otorhinolaryngol. 85(1), 37–42 (2019). https://doi.org/10.1016/j.bjorl.2017.10.005

    Article  PubMed  Google Scholar 

  9. E. Karvounis, I. Kappas, A. Angelousi et al. The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: a retrospective cohort study and systematic review of the literature. Oncol. Rev. 14(2), 439 (2020). https://doi.org/10.4081/oncol.2020.439

    Article  CAS  PubMed  Google Scholar 

  10. Y. Ju, L. Wang, F. Cheng et al. Comparing the efficacy of thyroglobulin and thyroglobulin/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy. BMC Endocr. Disord. 23(1), 19 (2023). https://doi.org/10.1186/s12902-022-01261-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. C. Lu, C. Wang, F. Li et al. The influence of stimulated thyroglobulin and lymphocyte subsets before radioiodine therapy on the therapeutic response in patients with intermediate- and high-risk papillary thyroid carcinoma. Clin. Exp. Med. (2022). https://doi.org/10.1007/s10238-022-00932-y

  12. N. Dessoki, I. Nasr, A. Badawy et al. Value of the postablative thyroglobulin measurements for assessment of disease-free status in patients with differentiated thyroid cancer. Indian J. Nucl. Med. 34(2), 118–124 (2019). https://doi.org/10.4103/ijnm.IJNM_142_18

    Article  PubMed  PubMed Central  Google Scholar 

  13. R.M. Tuttle, H. Tala, J. Shah et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20(12), 1341–1349 (2010). https://doi.org/10.1089/thy.2010.0178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. A.E. Llamas-Olier, D.I. Cuéllar, G. Buitrago, Intermediate-risk papillary thyroid cancer: risk factors for early recurrence in patients with excellent response to initial therapy. Thyroid® 28(10), 1311–1317 (2018). https://doi.org/10.1089/thy.2017.0578

    Article  CAS  PubMed  Google Scholar 

  15. Y. Zhang, C. Zhang, Y. Ma et al. Prediction to the prognosis of children with neuroblastoma by nomogram based on the first-diagnosed inflammatory markers. Pediatr. Surg. Int. 39(1), 17 (2022). https://doi.org/10.1007/s00383-022-05302-z

    Article  PubMed  Google Scholar 

  16. R. Zhao, Z. Liang, K. Chen et al. Nomogram based on inflammatory biomarkers and nutritional indicators for predicting overall survival in locoregionally advanced nasopharyngeal carcinoma. J. Inflamm. Res. 15, 2971–2981 (2022). https://doi.org/10.2147/jir.S366299

    Article  PubMed  PubMed Central  Google Scholar 

  17. Z. Zheng, R. Guan, Y. Zou et al. Nomogram based on inflammatory biomarkers to predict the recurrence of hepatocellular carcinoma-a multicentre experience. J. Inflamm. Res. 15, 5089–5102 (2022). https://doi.org/10.2147/jir.S378099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Y. Chen, C. Yu, D. Chen et al. A prognostic nomogram based on risk assessment for invasive micropapillary carcinoma of the breast after surgery. Cancer Med. 12(7), 8050–8062 (2023). https://doi.org/10.1002/cam4.5595

    Article  PubMed  PubMed Central  Google Scholar 

  19. R. Wu, W. Liu, N. Li et al. Analysis of correlation factors influencing the outcome of initial 131I remnant ablative therapy in intermediate- to high-risk patients with papillary thyroid microcarcinoma. Nucl. Med Commun. 43(6), 669–674 (2022). https://doi.org/10.1097/mnm.0000000000001554

    Article  CAS  PubMed  Google Scholar 

  20. P.G. Trevizam, J.V. Tagliarini, E.C. Castilho et al. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic (131)I in the differentiated thyroid cancers. Endocr. Res. 42(1), 42–48 (2017). https://doi.org/10.3109/07435800.2016.1173056

    Article  CAS  PubMed  Google Scholar 

  21. Y. Li, M. Rao, C. Zheng et al. Analysis of factors influencing the clinical outcome after surgery and (131)I therapy in patients with moderate-risk thyroid papillary carcinoma. Front. Endocrinol. 13, 1015798 (2022). https://doi.org/10.3389/fendo.2022.1015798

    Article  Google Scholar 

  22. P. Yazici, M. Mihmanli, E. Bozkurt et al. Which is the best predictor of thyroid cancer: thyrotropin, thyroglobulin or their ratio? Hormones 15(2), 256–263 (2016). https://doi.org/10.14310/horm.2002.1677

    Article  PubMed  Google Scholar 

  23. P. Trimboli, G. Treglia, L. Giovanella, Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules: a systematic review. Horm. Metab. Res. 47(4), 247–252 (2015). https://doi.org/10.1055/s-0034-1395517

    Article  CAS  PubMed  Google Scholar 

  24. N. Hulikal, A. Re, M. Banoth et al. Can preoperative serum thyroglobulin levels predict the risk of malignancy? Results from prospective analysis of biochemical predictors of malignancy in thyroid nodules. Acta Otorhinolaryngol. Ital. 40(1), 33–37 (2020). https://doi.org/10.14639/0392-100x-n0276

    Article  PubMed  PubMed Central  Google Scholar 

  25. H. Kim, S.Y. Park, J.H. Choe et al. Preoperative serum thyroglobulin and its correlation with the burden and extent of differentiated thyroid cancer. Cancers 12(3), (2020). https://doi.org/10.3390/cancers12030625

  26. H. Wang, S. Zhao, C. Xu et al. Clinical value of ultrasonography and serum markers in preoperative N staging of thyroid cancer. Cells 11(22), (2022). https://doi.org/10.3390/cells11223621

  27. Y. Feng, Y. Min, H. Chen et al. Construction and validation of a nomogram for predicting cervical lymph node metastasis in classic papillary thyroid carcinoma. J. Endocrinol. Invest. 44(10), 2203–2211 (2021). https://doi.org/10.1007/s40618-021-01524-5

    Article  CAS  PubMed  Google Scholar 

  28. C.J. Cao, C.Y. Dou, J. Lian et al. Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis. Oncol. Lett. 15(5), 8141–8148 (2018). https://doi.org/10.3892/ol.2018.8270

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Y. Lu, L. Jiang, C. Chen et al. Clinicopathologic characteristics and outcomes of papillary thyroid carcinoma in younger patients. Medicine 99(15), e19795 (2020). https://doi.org/10.1097/md.0000000000019795

    Article  PubMed  PubMed Central  Google Scholar 

  30. F. Demir, F.S. Şimşek, T. Ansal Balcı, The role of pre-ablative stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio for predicting metastasis in thyroid cancer. Mol. Imaging Radionucl. Ther. 28(1), 21–26 (2019). https://doi.org/10.4274/mirt.galenos.2018.09825

    Article  PubMed  PubMed Central  Google Scholar 

  31. H.J. Jiang, P.J. Hsiao, Clinical application of the ultrasound-guided fine needle aspiration for thyroglobulin measurement to diagnose lymph node metastasis from differentiated thyroid carcinoma-literature review. Kaohsiung J. Med Sci. 36(4), 236–243 (2020). https://doi.org/10.1002/kjm2.12173

    Article  CAS  PubMed  Google Scholar 

  32. C. Wang, H. Diao, P. Ren et al. Efficacy and affecting factors of (131)I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma. Front. Oncol. 8, 640 (2018). https://doi.org/10.3389/fonc.2018.00640

    Article  PubMed  PubMed Central  Google Scholar 

  33. B. Barres, A. Kelly, F. Kwiatkowski et al. Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers. J. Clin. Endocrinol. Metab. 104(8), 3462–3472 (2019). https://doi.org/10.1210/jc.2018-02680

    Article  PubMed  Google Scholar 

  34. W. Zheng, Z. Rui, X. Wang et al. The influences of TSH stimulation level, stimulated Tg level and Tg/TSH ratio on the therapeutic effect of (131)I treatment in DTC patients. Front Endocrinol. 12, 601960 (2021). https://doi.org/10.3389/fendo.2021.601960

    Article  Google Scholar 

  35. S. Zubair Hussain, M.U. Zaman, S. Malik et al. Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I(131)remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J. Thyroid Res. 2014, 610273 (2014). https://doi.org/10.1155/2014/610273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. S. Wu, H. Wang, Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer. Ann. Endocrinol. 74(1), 40–44 (2013). https://doi.org/10.1016/j.ando.2012.11.007

    Article  CAS  Google Scholar 

  37. T. Zhao, J. Liang, T. Li et al. Serial stimulated thyroglobulin measurements are more specific for detecting distant metastatic differentiated thyroid cancer before radioiodine therapy. Chin. J. Cancer Res. 29(3), 213–222 (2017). https://doi.org/10.21147/j.issn.1000-9604.2017.03.07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors acknowledged the facilities provided by the First Affiliated Hospital of Soochow University and Suzhou Science and Technology Town Hospital.

Author contributions

R.W. designed the study, analyzed the data, and wrote the manuscript. C.C. and M.Z. collected the data. Y.Y. and B.Z. designed the study and revised the manuscript. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, First Affiliated Hospital of Soochow University, Suzhou, China

    Runze Wen, Min Zhao & Bin Zhang

  2. Department of Nuclear Medicine, Suzhou Science and Technology Town Hospital, Suzhou, China

    Chang Chen & Yi Yang

Authors
  1. Runze Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin Zhang.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wen, R., Zhao, M., Chen, C. et al. A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate‑ and high‑risk differentiated thyroid cancer patients: a bi-center retrospective study. Endocrine 84, 989–998 (2024). https://doi.org/10.1007/s12020-023-03625-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-023-03625-y

Keywords

Search

Navigation